RxDoctor Payments Data

Roui Lorenzo de Castro, MD

Internal Medicine · Ewa Beach, HINPI 1346777059

Payments from drug & device makers

$543in general payments, 2019–2025

Across 23 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$139
  • Amgen$132
  • Gilead$69
  • Novo Nordisk$62
  • Lilly USA, LLC$45
  • Sanofi Pasteur Inc.$28
  • plus $68 from 3 others

What the payments were for

  • Food & beverage$543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$543 in reported general payments places this provider in the 60th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$49,615
Medicare patients
182
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$130,103
OzempicSemaglutide57$121,395
EliquisApixaban50$77,535
RybelsusSemaglutide19$37,439
MounjaroTirzepatide30$36,854
ProliaDenosumab17$29,645
TrulicityDulaglutide22$27,066
FarxigaDapagliflozin Propanediol15$12,809
Atorvastatin Calcium434$11,299
VascepaIcosapent Ethyl17$8,088
Tresiba Flextouch U-100Insulin Degludec15$6,854
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,657
SymbicortBudesonide/Formoterol Fumarate15$3,955
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,410
Novolog FlexpenInsulin Aspart13$2,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$62$158,83376 claims
Boehringer IngelheimJardiance$28$130,10390 claims
Lilly USA, LLCMounjaro, Trulicity$45$63,92052 claims
AmgenProlia$132$29,64517 claims
AstraZenecaFarxiga, Symbicort$20$16,76430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Ewa Beach

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →